Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H16O3 |
Molecular Weight | 208.2536 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(OC)=C(OC)C=C1\C=C\C
InChI
InChIKey=RKFAZBXYICVSKP-AATRIKPKSA-N
InChI=1S/C12H16O3/c1-5-6-9-7-11(14-3)12(15-4)8-10(9)13-2/h5-8H,1-4H3/b6-5+
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/28732807Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/29042206 | https://www.ncbi.nlm.nih.gov/pubmed/29032344 | https://www.ncbi.nlm.nih.gov/pubmed/15679319 | https://www.ncbi.nlm.nih.gov/pubmed/25311563 |
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28732807
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/29042206 | https://www.ncbi.nlm.nih.gov/pubmed/29032344 | https://www.ncbi.nlm.nih.gov/pubmed/15679319 | https://www.ncbi.nlm.nih.gov/pubmed/25311563 |
α-Asarone is a phytochemical compound with neuroprotective, anti-oxidative, anticonvulsive and cognitive enhancing action, isolated from the Chinese medicinal herb Acorus tatarinowii. Numerous clinical studies in China had indicated the effectiveness of α-asarone against respiratory disorders and epilepsy. Asarone tablets have been clinically used as bronchial asthma and bronchitis prescription drug in China. Unfortunately, toxic and genotoxic studies of a-asarone have indicated that this compound may pose a risk to human health, including embryotoxicity and maternal toxicity in rats, hepatotoxicity in rat-cultivated hepatocytes, and in vivo and in vitro genotoxic damage in mammalian cells.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29042206
Curator's Comment: Known to be CNS penetrant in mouse. Human data not available
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL340 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15679319 |
92.3 µM [IC50] | ||
Target ID: CHEMBL402 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25311563 |
5.86 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28732807
ICR mice/ Male: 10,15,20, 30, 50 and 100mg/kg i.p.
Swiss albino mice/male: 1. 7, 3.5, 7, and 14; p.o.; o.d.× 7 days
SD rats/ male: 50, 100 and 200; i.p.; o.d.× 21 days
Wistar rats/male: 20 mg/kg, i.v.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25983275
BV-2 microglial cells were used for activity evaluation. Cells were cultured in DMEM supplemented with 5% FBS and 50 mkg/mL penicillin-streptomycin in a 37 C humidified incubator supplied with 5% CO2 and 95% O2. The cells were seeded at a density of 5 x 10^4 cells/mL and were pretreated for 1 h with various concentrations of a-asarone (10, 50 and 250 mkM) followed by an incubation with LPS (100 ng/mL) for the indicated times (30 min and 6, 18 and 24 h).
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000151877
Created by
admin on Fri Dec 15 17:18:12 GMT 2023 , Edited by admin on Fri Dec 15 17:18:12 GMT 2023
|
PRIMARY | |||
|
220-743-6
Created by
admin on Fri Dec 15 17:18:12 GMT 2023 , Edited by admin on Fri Dec 15 17:18:12 GMT 2023
|
PRIMARY | |||
|
SUB126297
Created by
admin on Fri Dec 15 17:18:12 GMT 2023 , Edited by admin on Fri Dec 15 17:18:12 GMT 2023
|
PRIMARY | |||
|
DTXSID00871878
Created by
admin on Fri Dec 15 17:18:12 GMT 2023 , Edited by admin on Fri Dec 15 17:18:12 GMT 2023
|
PRIMARY | |||
|
636822
Created by
admin on Fri Dec 15 17:18:12 GMT 2023 , Edited by admin on Fri Dec 15 17:18:12 GMT 2023
|
PRIMARY | |||
|
C012195
Created by
admin on Fri Dec 15 17:18:12 GMT 2023 , Edited by admin on Fri Dec 15 17:18:12 GMT 2023
|
PRIMARY | |||
|
2375532
Created by
admin on Fri Dec 15 17:18:12 GMT 2023 , Edited by admin on Fri Dec 15 17:18:12 GMT 2023
|
PRIMARY | |||
|
78309
Created by
admin on Fri Dec 15 17:18:12 GMT 2023 , Edited by admin on Fri Dec 15 17:18:12 GMT 2023
|
PRIMARY | |||
|
3464
Created by
admin on Fri Dec 15 17:18:12 GMT 2023 , Edited by admin on Fri Dec 15 17:18:12 GMT 2023
|
PRIMARY | |||
|
DQY9PNE5FK
Created by
admin on Fri Dec 15 17:18:12 GMT 2023 , Edited by admin on Fri Dec 15 17:18:12 GMT 2023
|
PRIMARY | |||
|
2883-98-9
Created by
admin on Fri Dec 15 17:18:12 GMT 2023 , Edited by admin on Fri Dec 15 17:18:12 GMT 2023
|
PRIMARY | |||
|
ASARONE
Created by
admin on Fri Dec 15 17:18:12 GMT 2023 , Edited by admin on Fri Dec 15 17:18:12 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD